Co-Diagnostics, Inc. (LON:0A50)

Market Cap	11.69M +62.4%
Revenue (ttm)	543.87K -79.5%
Net Income	-36.73M
EPS	-22.59
Shares Out	n/a
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	582
Open	4.540
Previous Close	4.700
Day's Range	4.270 - 4.870
52-Week Range	1.290 - 46.173
Beta	1.26
Analysts	n/a
Price Target	n/a
Earnings Date	Aug 13, 2026

About Co-Diagnostics

Co-Diagnostics, Inc. operates as a molecular diagnostics company that develops, manufactures, and sells reagents used for diagnostic tests that function through the detection and/or analysis of nucleic acid molecules in the United States and internationally. It offers Co-Dx PCR platform, a polymerase chain reaction testing to patients in point-of-care and at-home setting. The company also provides PCR diagnostic tests for COVID-19, influenza, tuberculosis, hepatitis B and C, malaria, dengue, human papillomavirus, chikungunya, and Zika virus. In...

• Industry: In Vitro and In Vivo Diagnostic Substances
• Founded: 2013
• Employees: 115
• Stock Exchange: London Stock Exchange
• Ticker Symbol: 0A50

Financial Performance

In 2025, Co-Diagnostics's revenue was $622,489, a decrease of -84.10% compared to the previous year's $3.92 million. Losses were -$46.90 million, 24.6% more than in 2024.

Financial numbers in USD